Authors: Sadler, BM Chittick, GE Polk, RE Slain, D Kerkering, TM Studenberg, SD Lou, Y Moore, KHP Woolley, JL Stein, DS

Citation: Bm. Sadler et al., Metabolic disposition and pharmacokinetics of [C-14]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects, J CLIN PHAR, 41(4), 2001, pp. 386-396

Authors: Huang, LY Wring, S Woolley, JL Brouwer, KR Serabjit-Singh, C Polli, JW

Citation: Ly. Huang et al., Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors, DRUG META D, 29(5), 2001, pp. 754-760

Authors: Pudney, M Gutteridge, W Zeman, A Dickins, M Woolley, JL

Citation: M. Pudney et al., Atovaquone and proguanil hydrochloride: A review of nonclinical studies, J TRAVEL M, 6, 1999, pp. S8-S12

Authors: de Serres, M Yeager, RL Dillberger, JE Lalonde, G Gardner, GH Rubens, CA Simkins, AH Sailstad, JM McNulty, MJ Woolley, JL

Citation: M. De Serres et al., Pharmacokinetics and hematological effects of the PEGylated thrombopoietinpeptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration, STEM CELLS, 17(6), 1999, pp. 316-326

Authors: Polli, JW Jarrett, JL Studenberg, SD Humphreys, JE Dennis, SW Brouwer, KR Woolley, JL

Citation: Jw. Polli et al., Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor, PHARM RES, 16(8), 1999, pp. 1206-1212